Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone

Annals of Hematology

Volumn 88, Issue 2, 2009, Pages 167-172

  Trappe, Ralf ^a   Riess, H ^a   Anagnostopoulos, I ^a   Neuhaus, R ^a   Gartner B C ^b   Pohl, H ^a   Muller H P ^a   Jonas, S ^a   Papp Vary, M ^a   Oertel, S ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BASILIXIMAB; CIDOFOVIR; CYCLOPHOSPHAMIDE; DOXORUBICIN; FIBRINOGEN; FOSCARNET; HEMOGLOBIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; VINCRISTINE;

ADULT; CASE REPORT; COLITIS; COLON BIOPSY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; ECHOGRAPHY; EPSTEIN BARR VIRUS; ERYTHROCYTE TRANSFUSION; FEVER; GASTROINTESTINAL HEMORRHAGE; HERPES VIRUS INFECTION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LEUKOCYTE COUNT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE CYCLE TREATMENT; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; VIRUS LOAD;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS;

EID: 58149101410     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0538-0     Document Type: Letter

References (16)

1. Trappe R, Choquet S, Oertel S, Leblond V, Ekman T, Sender M et al (2007) Sequential treatment with rituximab and chop chemotherapy in b-cell ptld - a new standard in therapy. Blood 110:390
2. Oertel SH, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB (2002) Identification of early antigen bzlf1/zebra protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease. Br J Haematol 118:1120-1123 doi: 10.1046/j.1365-2141.2002.03764.x
3. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N et al (2005) Effect of anti-cd 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (ptld). Am J Transplant 5:2901-2906 doi: 10.1111/j.1600-6143.2005.01098.x
4. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P et al (2006) Efficacy and safety of rituximab in b-cell post-transplant lymphoproliferative disorders: Results of a prospective multicentre phase ii study. Blood 107:3053-3057 doi: 10.1182/blood-2005-01-0377
5. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, Gomez-Codina J, Salar A, Bailen A et al (2007) Prospective phase ii trial of extended treatment with rituximab in patients with b-cell post-transplant lymphoproliferative disease. Haematologica 92:1489-1494 doi: 10.3324/ haematol.11360
6. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Sakamoto K, Purtilo DT, Balfour HH Jr et al (1982) Epstein-Barr virus-induced b-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal b-cell proliferation. N Engl J Med 306:913-918
7. Hanto DW (1995) Classification of Epstein-Barr virus-associated posttransplant lymphoproliferative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies. Annu Rev Med 46:381-394 doi: 10.1146/annurev.med.46.1.381
8. Rees L, Thomas A, Amlot PL (1998) Disappearance of an Epstein-Barr virus-positive post-transplant plasmacytoma with reduction of immunosuppression. Lancet 352:789 doi: 10.1016/S0140-6736(05)60684-8
9. Reisman RP, Greco MA (1984) Virus-associated hemophagocytic syndrome due to Epstein-Barr virus. Hum Pathol 15:290-293 doi: 10.1016/ S0046-8177(84)80194-X
10. Sester M, Sester U, Gartner BC, Girndt M, Meyerhans A, Kohler H (2002) Dominance of virus-specific cd8 t cells in human primary cytomegalovirus infection. J Am Soc Nephrol 13:2577-2584 doi: 10.1097/ 01.ASN.0000030141.41726.52
11. Rentenaar RJ, Gamadia LE, van DerHoek N, van Diepen FN, Boom R, Weel JF et al (2000) Development of virus-specific cd4(+) t cells during primary cytomegalovirus infection. J Clin Invest 105:541-548 doi: 10.1172/JCI8229
12. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA et al (2000) Early highly active antiretroviral therapy for acute hiv-1 infection preserves immune function of cd8+ and cd4+ t lymphocytes. Proc Natl Acad Sci U S A 97:3382-3387 doi: 10.1073/ pnas.97.7.3382
13. Opelz G, Daniel V, Naujokat C, Fickenscher H, Dohler B (2007) Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: A multicentre retrospective analysis. Lancet Oncol 8:212-218 doi: 10.1016/S1470-2045(07)70040-2
14. Abedi MR, Linde A, Christensson B, Mackett M, Hammarstrom L, Smith CI (1997) Preventive effect of IgG from EBV-seropositive donors on the development of human lympho-proliferative disease in SCID mice. Int J Cancer 71:624-629 doi: 10.1002/ (SICI)1097-0215(19970516)71:4<624::AID-IJC19>3.0.CO;2-B
15. Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ (2002) Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 74:367-372 doi: 10.1097/00007890-200208150-00013
16. Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M et al (2006) Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 85:478-484 doi: 10.1007/ s00277-006-0109-1